...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ClinicoEconomics and Outcomes Research >Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy
【24h】

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy

机译：意大利先进皮肤鳞状细胞癌患者Cemimpab的初步成本效益及成本实用性分析

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Cutaneous squamous cell carcinoma (CSCC) is a common cancer that in most cases is curable with surgery. About 3– 5% of patients develop advanced CSCC (aCSCC) and are no longer responsive to surgery or radiation therapy. The aim of this study was to assess the cost-effectiveness and cost-utility of cemiplimab, the first systemic therapy approved in Italy for patients with aCSCC, vs platinum-based chemotherapy from the Italian National Health Service (SSN) perspective. Methods: A partitioned survival model, which included three mutually exclusive health states, was developed to estimate costs and outcomes for patients with aCSCC, over a 30-year time horizon (lifetime). No direct evidence of the comparative efficacy and safety of cemiplimab versus other therapies currently exists. Therefore, a simulated treatment comparison (STC) was conducted to estimate the comparative efficacy of cemiplimab versus chemotherapy. Individual patient data for cemiplimab were collected from the EMPOWER-CSCC 1 trial whereas chemotherapy data were derived from a retrospective study. In the STC a regression model was used to predict outcomes for cemiplimab in the population observed in the comparator study. Costs of drug acquisition/administration and management of adverse events were included. Costs and outcomes were discounted at 3% per year. Incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) were calculated; sensitivity and scenario analyses were performed to assess the robustness of results. Results: In the base-case, treatment with cemiplimab was associated with a gain of 4.89 LYs and 3.99 QALYs, compared with a platinum-based chemotherapy regimen, resulting in an estimated ICER of 27,821 €/LY gained and an ICUR of 34,110 €/QALY gained. Both ICER and ICUR were below the commonly used Italian SSN willingness to pay thresholds. Conclusion: The use of cemiplimab, compared with a platinum-based chemotherapy regimen, can be considered a cost-effective option for the treatment of aCSCC patients in Italy.
机译：目的：皮肤鳞状细胞癌（CSCC）是一种常见的癌症，即在大多数情况下是用手术治愈的。大约3％的患者发育高级CSCC（ACSCC），不再对手术或放射治疗响应。本研究的目的是评估CeMimpab的成本效益和成本效用，意大利ACSCC患者批准的第一个全身疗法，从意大利国家卫生服务（SSN）的角度来看，VS铂族化疗。方法：制定了一个分区存活模型，其中包括三个相互专有的健康国家，以估算ACSCC患者的成本和结果，超过30年的时间（寿命）。目前，目前不存在Cemimpimab与其他疗法的比较疗效和安全性的直接证据。因此，进行了模拟处理比较（STC）以估计CeMimplimab与化疗的比较疗效。从Empower-CSCC 1试验中收集了CeMiplimab的个体患者数据，而化疗数据来自回顾性研究。在STC中，回归模型用于预测比较器研究中观察到的人群中CeMiplimab的结果。包括药物收购/管理和管理不良事件的成本。成本和结果每年3％折扣。计算增量成本效益比（ICER）和增量成本实用比（ICUR）;进行敏感性和情景分析以评估结果的稳健性。结果：在基本情况下，与基于铂的化疗方案相比，用CeMiplimab治疗与4.89 Lys和3.99 QALYS的增益相关，导致估计的27,821€/ LY的算术和34,110欧元的ICUR QALY获得了。这两人都均低于常用的意大利人SSN愿意支付门槛。结论：与铂类化疗方案相比，使用CeMiplimab，可被认为是治疗意大利ACSCC患者的成本效益的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号